EP Patent

EP0984930B1 — 2-indolinone derivatives as modulators of protein kinase activity

Assigned to Sugen LLC · Expires 2005-04-06 · 21y expired

What this patent protects

The present invention relates to novel 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such …

USPTO Abstract

The present invention relates to novel 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP0984930B1
Jurisdiction
EP
Classification
—
Expires
2005-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Sugen LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.